

Thermally Triggered Hydrogel Injection Into Bovine Intervertebral Disc Tissue Explants Induces Differentiation Of Mesenchymal Stem Cells And Restores Mechanical Function.

THORPE, Abbey, DOUGILL, G, VICKERS, Louise, REEVES, N, COOPER, G, SAMMON, Chris <<http://orcid.org/0000-0003-1714-1726>> and LE MAITRE, Christine <<http://orcid.org/0000-0003-4489-7107>>

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/15537/>

This document is the Accepted Version [AM]

Citation:

THORPE, Abbey, DOUGILL, G, VICKERS, Louise, REEVES, N, COOPER, G, SAMMON, Chris and LE MAITRE, Christine (2017). Thermally Triggered Hydrogel Injection Into Bovine Intervertebral Disc Tissue Explants Induces Differentiation Of Mesenchymal Stem Cells And Restores Mechanical Function. *Acta Biomaterialia*, 54, 212-226. [Article]

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

**Thermally Triggered Hydrogel Injection Into Bovine Intervertebral Disc Tissue
Explants Induces Differentiation Of Mesenchymal Stem Cells And Restores
Mechanical Function.**

Thorpe A.A¹, Dougill G², Vickers L¹, Reeves ND², Sammon C⁴, Cooper G³, Le Maitre
C.L^{1*}.

¹Biomolecular Sciences Research Centre, Sheffield Hallam University, UK, S1 1WB.

²Faculty of Science & Engineering, Manchester Metropolitan University M1 5GD.

³ School of Mechanical, Aerospace and Civil Engineering, University of Manchester,
M13 9PL.

⁴Materials and Engineering Research Institute, Sheffield Hallam University, UK, S1
1WB.

Thorpe AA: abbey.a.thorpe@student.shu.ac.uk

Dougill G: g.dougill@mmu.ac.uk

Vickers L: hwblv1@exchange.shu.ac.uk

Reeves N: n.reeves@mmu.ac.uk

Cooper G: glen.cooper@manchester.ac.uk

Sammon C: c.sammon@shu.ac.uk

Corresponding Author: *Dr Christine Lyn Le Maitre. Biomolecular Sciences Research
Centre, Sheffield Hallam University, S1 1WB. Email: c.lemaitre@shu.ac.uk

Phone +44 (0)114 225 6163 Fax +44 (0)114 225 3064

Abstract

We previously reported a synthetic Laponite® crosslinked pNIPAM-co-DMAc (L-pNIPAM-co-DMAc) hydrogel which promotes differentiation of mesenchymal stem cells (MSCs) to nucleus pulposus (NP) cells without additional growth factors. The clinical success of this hydrogel is dependent on: integration with surrounding tissue; the capacity to restore mechanical function; as well as supporting the viability and differentiation of delivered MSCs. Bovine NP tissue explants were injected with media (control), human MSCs (hMSCs) alone, acellular L-pNIPAM-co-DMAc hydrogel or hMSCs incorporated within the L-pNIPAM-co-DMAc hydrogel and maintained at 5% O₂ for 6 weeks. Viability of native NP cells and delivered MSCs was maintained. Furthermore hMSCs delivered via the L-pNIPAM-co-DMAc hydrogel differentiated and produced NP matrix components: aggrecan, collagen type II and chondroitin sulphate, with integration of the hydrogel with native NP tissue. In addition L-pNIPAM-co-DMAc hydrogel injected into collagenase digested bovine discs filled micro and macro fissures, were maintained within the disc during loading and restored IVD stiffness. The mechanical support of the L-pNIPAM-co-DMAc hydrogel, to restore disc height, could provide immediate symptomatic pain relief, whilst the delivery of MSCs over time regenerates the NP extracellular matrix; thus the L-pNIPAM-co-DMAc hydrogel could provide a combined cellular and mechanical repair approach.

Abbreviations

LBP: low back pain; IVD: Intervertebral disc; CEP: cartilaginous end plate; AF: annulus fibrosus; NP: nucleus pulposus; ECM: extracellular matrix; MSCs: mesenchymal stem cells; hMSCs: human mesenchymal stem cells; L-pNIPAM-co-

49 DMAc: Laponite® crosslinked pNIPAM-co-DMAc hydrogel; FCS: fetal calf serum,
50 NIPAM: N-isopropylacrylamide; DMAc: N, N' –dimethylacrylamide; AIBN: 2-2'-
51 azobisisobutyronitrile; SEM: scanning electron microscopy; IHC:
52 Immunohistochemistry.

53 **Keywords**

54 Intervertebral disc, Nucleus pulposus, Injectable hydrogel, Mesenchymal stem cells,
55 Tissue explant culture.

56 **1. Introduction**

57 Low back pain (LBP) is an increasingly prevalent clinical condition that affects over
58 80% of the population at some point during their lifetime [1]. The aetiology of chronic
59 LBP is thought to be multifactorial; however, degeneration of the intervertebral disc
60 (IVD) is regarded as a key attributing factor [2,3]. Morphologically the IVD can be
61 divided into three distinct regional structures: the cartilaginous endplates (CEP); the
62 annulus fibrosus (AF) and the central gelatinous nucleus pulposus (NP), rich in
63 proteoglycans (mainly aggrecan) and collagen type II [4]. The IVD transmits load,
64 facilitates a range of spinal movement and dissipates energy during motion [5].

65 Degeneration of the IVD is characterised by a number of progressive extracellular
66 matrix (ECM) changes including altered matrix synthesis and increased degradation
67 of normal matrix components [6], resulting in an overall reduction in the proteoglycan
68 content of the NP [7]. This is mediated by the catabolic phenotype of degenerate NP
69 cells [8,9] alongside decreased viability as well as increased apoptosis [17] and
70 senescence of remaining NP cells [10]. This results in reduced NP tissue hydration
71 and an overall loss in disc height [11], culminating in mechanical failure resulting in

abnormal stresses to surrounding spinal tissues and compression of nerve routes [12]. Consequently, the restoration of disc height is a key therapeutic target for the symptomatic relief of chronic LBP.

New approaches in tissue engineering have led to the investigation of a variety of treatment options aimed at the restoration of disc height using acellular implants [13-16], the use of regenerative cells [17-20] or the combined delivery of regenerative cells with supporting mechanical scaffolds [21,22]. Mesenchymal stem cells (MSCs) have been highlighted as an attractive cell choice since they have proliferative capacity, can be extracted from a variety of adult tissues and have the capacity to differentiate into NP like cells [19,20,23-25]. However, concerns remain regarding MSC leakage [26], as well as a lack of control over differentiation following injection [27], thus highlighting the potential need for cell carrier systems. The use of a combined approach is appealing, since it is hypothesised that the mechanical support of the biomaterial scaffold would provide immediate pain relief. Whilst the delivery of regenerative cells would provide a long term, gradual regeneration of an ECM which biologically functions, akin to native NP tissue. To date, a variety of biomaterial scaffolds have been investigated for repair of the NP. However injectable scaffolds with the potential to deliver cells, have not demonstrated the required mechanical robustness [14]. Whilst those developed as acellular NP replacement scaffolds have so far failed, due to poor integration resulting in extrusion or expulsion of the implanted material [14,28,29] or are unable to deliver regenerative cells to the IVD [13-16]. The implantation methodology is also an important consideration to minimise trauma to the existing IVD tissue [30,31].

We have previously reported the development of a synthetic Laponite® crosslinked pNIPAM-co-DMAc (L-pNIPAM-co-DMAc) hydrogel delivery system which has the potential to deliver human MSCs (hMSCs) via minimally invasive injection, using small bore needles (26G) which decrease the chance of inducing damage to the annulus fibrosus [23]. We have demonstrated *in vitro* that hMSCs incorporated into L-pNIPAM-co-DMAc hydrogels and cultured in 5% O₂, differentiated into NP-like cells, without the use of chondrogenic inducing medium or additional growth factors [23]. The clinical success of this hydrogel is dependent on: integration with surrounding tissue; the capacity to restore mechanical function; as well as supporting the viability and differentiation of delivered MSCs.

In the present study, we investigated the efficacy of several IVD repair strategies including: hMSCs alone, acellular L-pNIPAM-co-DMAc hydrogel or hMSCs incorporated within L-pNIPAM-co-DMAc hydrogel, injected into bovine NP tissue explants. This study tested the hypothesis that the delivery of hMSCs within the L-pNIPAM-co-DMAc hydrogel would aid scaffold integration, and promote differentiation of MSCs towards the correct NP cell phenotype within native NP tissue. We additionally investigated the mechanical function, defined in this study as disc apparent modulus, strain under load, energy dissipation, and restoration of hydrogel injected bovine IVDs following collagenase digestion. Together these investigations determine the capacity of this hydrogel to be used as both a cell delivery vehicle and as a mechanical support scaffold in the treatment of IVD degeneration.

2. Materials and Methods

2.1. Nucleus pulposus tissue explant culture

119 Bovine tails from 9 months old to 18 months old cows were obtained from the
120 abattoir. Caudal IVDs were excised and NP tissue was isolated. Cores of NP tissue
121 (0.5cm in diameter) were formed and placed in a Perspex® ring, in sterile 6 well
122 culture plates, as previously described [17]. Ten millilitres of DMEM media (Life
123 Technologies, Paisley UK) supplemented with 10% v/v heat inactivated foetal calf
124 serum (FCS) (Life Technologies, Paisley UK), 100U/ml penicillin (Life Technologies
125 Paisley UK), 100µg/ml streptomycin (Life Technologies Paisley UK), 250ng/ml
126 amphotericin (Sigma, Poole UK), 2mM glutamine (Life Technologies, Paisley UK)
127 and 10µg/ml ascorbic acid (Sigma, Poole UK) (complete cell culture media) was
128 applied and tissue explants and were maintained in culture for 48 hours prior to
129 hMSC and hydrogel injection.

130 **2.2. Hydrogel synthesis**

131 An exfoliated suspension of Laponite® clay nanoparticles (25-30nm diameter, <1nm
132 thickness) (BYK Additives Ltd, Cheshire UK) was prepared by vigorous stirring of
133 Laponite® (0.1g) in deionised H₂O (10ml) (18 MΩ) for 24 hours. N-
134 isopropylacrylamide 99% (NIPAM) (0.783g) (Sigma, Poole UK), N, N' -
135 dimethylacrylamide (DMAc) (0.117g) (Sigma, Gillingham UK) and 2-2'-
136 azobisisobutyronitrile (AIBN) (0.009g) (Sigma, Poole UK) were added to the
137 suspension and stirred for 1 hour. After passing the suspension through a 5-8µm
138 pore filter paper, polymerisation was initiated by heating to 80°C and the reagents
139 were allowed to react for 24 hours. Following 24 hours the hydrogel suspension was
140 cooled to 38-39°C prior to cell incorporation. Further cooling of the polymeric
141 suspension to 37°C, i.e. below the lower critical solution temperature (LCST),
142 resulted in rapid gelation to a solidified hydrogel, as previously described [23].

2.3. Mesenchymal stem cell source, expansion and transfer to nucleus pulposus tissue explants.

Commercial bone marrow derived human adult mesenchymal stem cells (hMSCs) extracted from a 39yr old donor (Lonza, Slough UK) were cultured in complete DMEM media (Life Technologies, Paisley UK). MSCs were expanded in monolayer culture to passage 7 to ensure sufficient cells were available. To allow cell tracking following injection, the MSCs were labelled with a fluorescent intracellular carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE) cell labelling kit, (Abcam, Cambridge, UK) according to manufacturer's instructions. Cell seeding solutions were prepared at a density of 4×10^6 cells/ml in either complete DMEM media or liquid hydrogel suspension (38-39°C) and then 50µl injected into the centre of NP tissue explants via 26 gauge needle injection (Becton Dickinson, Plymouth, UK). Fifty microliters of media or hydrogel suspension containing no cells was also injected via a 26 gauge needle (Becton Dickinson, Plymouth, UK) into NP tissue explants. This gave four experimental groups: media injected control (control), hMSC injected alone (hMSC), acellular L-pNIPAM-co-DMAc hydrogel (acellular Hy) and hMSC incorporated within L-pNIPAM-co-DMAc hydrogel (hMSC + Hy) injected NP tissue explants. All NP tissue explants were cultured in complete DMEM cell culture media via careful overlay of 10ml of media per NP tissue explant, incubated at 37°C, 5% CO₂ and maintained in culture for up to 6 weeks in an oxygen controlled glove box (Coy Lab products, York, UK) at 5% O₂. Media was replaced every 2-3 days. Samples were removed after 48 hours, 2, 4 and 6 weeks for analysis of cell viability, scanning electron microscopy (SEM), histological assessment of matrix deposition and NP cell phenotype analysis using immunohistochemistry (IHC).

2.4. Cytospins

IHC was performed on MSCs taken from monolayer culture prior to injection into NP tissue explants to serve as time zero controls. Monolayer cells were trypsinised and cells fixed in 4% w/v paraformaldehyde/PBS (Sigma, Poole UK) for 20min, spun at 300g for 5 min to form a cell pellet and resuspended in PBS to a cell density of 300 cells per microlitre. One hundred microlitres of cell suspension was then cytospun, formed via centrifugation at 1000rpm for 3 min (Shandon Cytospin 3, Thermo Scientific, Loughborough UK). Slides were subsequently air-dried and stored at 4°C until required for IHC analysis.

2.5. Processing of tissue explants and identification of the injection site:

Triplicate NP tissue explants of each experimental group: control, hMSC alone, acellular Hy and hMSC + Hy, were fixed in 10% w/v formalin (Leica Microsystems, Milton Keynes UK) overnight prior to routine paraffin embedding. Tissue samples were serially sectioned at 4µm, perpendicular to the needle injection, and two sections every 100µm were mounted onto positively charged slides (Leica Microsystems, Milton Keynes UK). Sections were air-dried, dewaxed in Sub-X (Leica Microsystems, Milton Keynes UK), dehydrated in industrial methylated spirit (IMS) (Fisher, Loughborough UK), washed in deionised H₂O and then stained with either routine haematoxylin and eosin (H&E) (Leica Microsystems, Milton Keynes UK) histological staining or Hoechst nuclear fluorescent staining (Sigma, Poole UK). Slides stained for H&E were immersed in Mayers haematoxylin for 2 minutes, rinsed in water for 5 minutes, immersed in eosin for 2 minutes, dehydrated in IMS, cleared in Sub-X and mounted in Pertex® (Leica Microsystems, Milton Keynes UK). Slides stained with Hoechst were immersed in 5pg/mL **Hoechst**/PBS, incubated for 10min,

washed 3 times in PBS and mounted in 90% v/v glycerol/PBS. Slides were then visualised using light and fluorescent microscopy with an Olympus BX51 microscope and images captured by digital camera and Capture Pro OEM v8.0 software (Media Cybernetics, Buckinghamshire, UK) to identify the injection site and distinguish native NP cells (Hoechst+/CFSE-) and injected hMSCs (Hoechst+/CFSE+). Within control NP explants, the injection site was identified where the needle track could be seen histologically (within early time points) or halfway through the entire depth of the NP tissue explant. Where MSCs were injected alone injection site was determined via the identification of CFSE positive cells. Where acellular L-pNIPAM-co-DMAc or L-pNIPAM-co-DMAc with incorporated MSCs had been injected, the injection site was determined by the histological identification of the hydrogel. Following identification of the position of the injection site and the presence of CFSE positive cells, serial sections in the area of the injection site were mounted onto positively charged slides: for caspase 3 IHC to identify the presence of apoptotic cells, histological assessment of matrix components using Alcian blue and Masson trichrome as well as IHC for aggrecan, chondroitin sulphate and collagen type II to assess phenotypic characteristics.

2.6. Structural and Mechanical Characterisation

2.6.1. Scanning electron microscopy (SEM).

Samples were removed from culture after 48 hours and 6 weeks, frozen at -80°C and subsequently freeze dried using a FD-1A-50 freeze drier set to -53°C, 3.8×10^{-4} mbar overnight. The sample was then fractured to expose the interior surface morphology attached onto an aluminium stub and then using a Quorum Technology

215 150 Q TES system coated with gold (10µA sputter current for 180 seconds with a 2.7
216 tooling factor) for imaging.

217 The fractured surfaces were examined using a FEI NOVA nanoSEM 200 scanning
218 electron microscope (SEM). Secondary electron images were obtained using
219 accelerating voltage 5KV at various magnifications ranging from 1000x to 40,000x.

220 **2.6.2. Hydration degree**

221 To evaluate the hydration degree of NP tissue explants, samples were extracted
222 from culture in triplicate following 48 hours, 2, 4 and 6 weeks and the wet weight (M_0)
223 of the NP tissue explants was measured. Samples were then freeze dried using a
224 FD-1A-50 freeze drier set to -53 °C, 3.8×10^{-4} mbar overnight to obtain the dry
225 weight (M_t). The hydration degrees of the NP tissue explants were calculated using
226 eq1:

$$Hydration\ degree = \frac{(M_0 - M_t)}{M_0} \times 100$$

227 (1)

228 **2.6.3. Dynamic mechanical analysis**

229 The mechanical properties of NP tissue explants were characterised following 6
230 weeks in culture. Replicate samples were removed from culture, blotted and their
231 mechanical properties characterised by DMA. Samples were trimmed using a 5mm
232 circumference circular biopsy punch from the centre of NP tissue explants, all
233 sample heights were measured and recorded using digital callipers prior to
234 measurement. Triplicate samples were analysed using a PerkinElmer DMA8000

235 model under confined compression mode at 25 °C, applying a sinusoidal force with a
236 0.02mm displacement at 2.5Hz.

237 **2.7. Histological evaluation of matrix components**

238 Matrix deposition around the injection site of NP tissue explants was investigated
239 following 48 hours, 2, 4 and 6 weeks in triplicate. Sections were dewaxed in Sub-X,
240 dehydrated in IMS, washed in deionised H₂O and then stained using histological
241 stains: 1% w/v Alcian blue (pH 2.5) (Sigma Aldrich, Poole UK) in 3% v/v acetic acid
242 (Sigma Aldrich, Poole UK) for 5 minutes with 1% Neutral red w/v (Sigma Aldrich,
243 Poole UK) used as a counter stain for 2 minutes or Masson trichrome (Bio-Optica,
244 Miller & Miller (Chemicals) Ltd, Hainault UK) according to the manufacturer's
245 instructions. Sections were dehydrated in IMS, cleared in Sub-X and mounted in
246 Pertex® (Leica Microsystems, Milton Keynes UK). All slides were examined with an
247 Olympus BX51 microscope and images captured by digital camera and Capture Pro
248 OEM v8.0 software (Media Cybernetics, Buckinghamshire, UK). Histological sections
249 were analysed, features noted and images captured to document their histological
250 appearance.

251 **2.8. Immunohistochemistry assessment of apoptosis and phenotypic** 252 **characteristics.**

253 Caspase 3 as a marker of apoptosis and NP matrix markers: aggrecan, collagen
254 type II and chondroitin sulphate were selected for immunohistochemistry (IHC) to
255 assess the viability and phenotypic characteristics of NP tissue explants and
256 delivered hMSCs. IHC was performed as previously described [32]. Briefly, 4µm
257 paraffin sections were de-waxed, rehydrated and endogenous peroxidase-blocked
258 using hydrogen peroxide (Sigma, Aldrich Poole UK). After washing in tris-buffered

259 saline (TBS; 20 mM tris, 150 mM sodium chloride, pH 7.5) sections were subjected
 260 to antigen retrieval methods (Table I). Following TBS washing, nonspecific binding
 261 sites were blocked at room temperature for 90 minutes with 25% w/v serum (Abcam,
 262 Cambridge, UK) (Table I) in 1% w/v bovine serum albumin in TBS. Sections were
 263 incubated overnight at 4°C with the appropriate primary antibody (Table I). Negative
 264 controls in which mouse or rabbit IgGs (Abcam Cambridge UK) replaced the primary
 265 antibody at an equal protein concentration were used (Table I). After washing in
 266 TBS, sections were incubated in 1:500 biotinylated secondary antibody (Table I).
 267 Disclosure of secondary antibody binding was by the HRP-streptavidin biotin
 268 complex (30 minute incubation) (Vector Laboratories, Peterborough, UK), TBS
 269 washing, followed by application of 0.08% v/v hydrogen peroxide in 0.65 mg/ml 3,3'-
 270 diaminobenzidine tetrahydrochloride (Sigma Aldrich, Poole UK) in TBS (20 minute
 271 incubation). Sections were counterstained with Mayer's haematoxylin, dehydrated in
 272 IMS, cleared in Sub-X and mounted in Pertex®. All slides were visualised using an
 273 Olympus BX51 microscope and images captured by digital camera and Capture Pro
 274 OEM v8.0 software (Media Cybernetics, Buckinghamshire, UK). Evaluation of
 275 caspase 3 IHC staining was performed by counting immunopositive and
 276 immunonegative cells for each section and immunopositive cells expressed as a
 277 percentage of the total count. Images were captured for IHC staining of NP markers:
 278 aggrecan, collagen type II and chondroitin sulphate to qualitatively analyse the
 279 injection site, native disc cells/injected cells and surrounding matrix.

Target Antibody	Clonality	Optimal Dilution	Antigen Retrieval	Secondary Antibody	Serum Block
Caspase 3	Rabbit Polyclonal	1:400	None	Goat anti Rabbit	Goat
Aggrecan	Mouse Monoclonal	1:100	Heat	Rabbit anti mouse	Rabbit

Collagen II	type	Mouse Monoclonal	1:200	Enzyme	Rabbit anti mouse	Rabbit
Chondroitin Sulphate		Mouse Monoclonal	1:400	Enzyme	Rabbit anti mouse	Rabbit

Table I: Target antibodies used for IHC, their optimal concentrations and antigen retrieval methods. Heat antigen retrieval consisted of 10-minute microwave irradiation in 0.05M tris buffer, pH 9.5 pre-heated to 60°C. Enzyme antigen retrieval consisted of 30-minute incubation in TBS; 20 mM tris, 150 mM sodium chloride, 46.8mM calcium chloride dihydrate pH 7.5, containing 0.01% w/v α -chymotrypsin from bovine pancreas at 37°C.

2.9 Mechanical characterisation of L-pNIPAM-co-DMAc hydrogel injected whole bovine IVDs.

2.9.1. IVD Isolation and Collagenase Digestion

Bovine tails from 9 to 18 month old cows were obtained from the abattoir, operating in concordance with animal welfare regulations. Tails were stored at -20°C shortly post sacrifice and tested a maximum of one month post storage. Tails were thawed at 5°C for 24 hours prior to sample preparation. Discs were dissected whole from tail sections between cd1-2 and cd4-5. Discs without parallel faces or with visible signs of damage were discarded. The remaining discs were allowed to equilibrate to room temperature for 12 hours before testing, between 2 and 4 discs were gained from each tail section. Discs were stored in airtight sealed bags to prevent dehydration during this time. Discs were randomly assigned to four test groups (n=10 per group): healthy; sham injected; collagenase digested and collagenase digested following hydrogel injected. Healthy discs were not experimentally manipulated following excision, sham injected discs were stabbed with a 21-gauge needle to assess the effect of needle insertion. Collagenase digested and hydrogel injected discs were

303 injected with 100-200µl of a 2mg/mL collagenase solution (Sigma, Poole, UK) in
304 distilled water (injection was performed until either the internal pressure in the disc
305 prevented any further injection or a maximum of 200µl had been injected) and
306 incubated for 2 hour at 37°C.

307 **2.9.2 Injection of L-pNIPAM-co-DMAc hydrogel in whole bovine IVDs**

308 Following collagenase digestion, discs to be injected with hydrogel were inspected
309 morphologically to ensure collagenase digestion had successfully induced void
310 formation. Hydrogel injected discs then received an injection of 50-200µL of acellular
311 L-pNIPAM-co-DMAc hydrogel, with an incorporated green food dye for visualisation.
312 Hydrogel injected discs were left 30 minutes post injection to allow the L-pNIPAM-co-
313 DMAc hydrogel to stabilize and mimic the operation time for the patient, prior to
314 testing. Injection protocol consisted of the syringe being depressed until either the
315 internal pressure in the disc prevented any further intake or a maximum of 200µl of
316 L-pNIPAM-co-DMAc hydrogel had been injected. All the needle tips were inserted
317 into the centre of the NP before injection of material. Visual inspection during
318 injection allowed needle position to be observed through the deformation of
319 surrounding material.

320 **2.9.3. Mechanical loading of IVDs**

321 Discs were loaded cyclically using a dynamic test rig incorporating a hydraulic piston
322 controlled by Wavematrix 1.8 test software and a Labtronic 8800 hydraulic controller
323 (Instron. Mass, USA). Discs were placed between two smooth parallel metal platens
324 without further constraint. Discs with non-parallel surfaces were rejected prior to
325 testing and no lateral movement was observed during testing (indicating that disc
326 surfaces were parallel and all deflection was in the axial direction). Discs were

subjected to a sinusoidal load between 0.53 and 0.65 MPa at 2 Hz to simulate walking based on known values from the literature [51-53]. Each disc was ramped to a preload at the midpoint between the upper and lower boundaries at a rate of 0.01 kN/s, immediately upon reaching the preload, cyclic loading was applied for 100 seconds, representative of a short period of activity typical of activities of daily living (ADLs) in all but the most severely impaired persons.

Three measures of mechanical response were tracked by the data acquisition tools connected to Wavematrix. Engineering stiffness of each disc was measured as the change in force divided by the change in displacement from minimum ($F_{min} = 0.53$ MPa \times disc cross-sectional area) to maximum ($F_{max} = 0.65$ MPa \times disc cross-sectional area) loading. Strain was measured as the displacement between those points divided by the disc height at minimum loading. Lastly the energy dissipated by discs during each loading/unloading cycle was calculated from the **hysteresis in the load deflection data**.

2.10. Data processing and statistical analysis

All tests were performed at least in triplicate. Data was assessed for normality using the Shapiro Wilks test and found to be non-parametric and hence statistical comparisons were performed by Kruskal-Wallis with a pairwise comparisons (Conover-Inman) post hoc test performed with statistical significance accepted at $p \leq 0.05$. Pairwise comparisons were made as follows: between all-time points and between the different experimental groups for caspase 3 immunopositivity; between the different experimental groups for mechanical analysis; hMSC alone, Acellular Hy and hMSC + Hy compared with media injected control NP explants for hydration

assessment at each given time point. Data was then presented on graphs; all replicates have been shown with median value indicated to demonstrate clearly the spread of replicates.

3. Results

3.1. Identification of injected L-pNIPAM-co-DMAc hydrogel and mesenchymal stem cells.

No CFSE (green) positive cells were identified within media injected controls or acellular hydrogel injected NP tissue explants (Fig 1). CFSE positive MSCs were identified where MSCs had been injected alone, where they remained in clusters at the vicinity of the injection site following 4 weeks in culture (Fig 1). Some CFSE positive cells appeared to have migrated away from the injection site following 6 weeks, although many were still in close proximity to each other (Fig 1). Infiltrating native NP cells stained with Hoechst were identified within the acellular L-pNIPAM-co-DMAc following 4 and 6 weeks in culture (Fig 1). CFSE positive MSCs were identified within the L-pNIPAM-co-DMAc hydrogel throughout the 6 week culture duration where they had been incorporated prior to injection (Fig 1). CFSE positive MSCs were also observed within the native NP tissue surrounding the hydrogel region following 6 weeks in culture (Fig 1).

3.2. Caspase 3 cell viability.

Low levels of apoptosis was observed in media injected control NP explant tissue, with no significant difference in the number of caspase 3 immunopositive cells throughout the 6 week culture duration (Fig 2a,b). Where acellular L-pNIPAM-co-DMAc hydrogel had been injected no significant difference in the number of caspase

3 immunopositive cells was observed between native NP cells within the surrounding NP tissue compared with native NP cells infiltrated within the hydrogel (Fig 2a,b). Low levels of apoptosis within MSCs injected alone, with no significant difference in the number of immunopositive cells observed throughout the 6 week culture duration (Fig 2a,b). Where MSCs were incorporated within L-pNIPAM-co-DMAc hydrogel prior to injection, no significant difference in the number of caspase 3 immunopositive cells was observed between cells found within the surrounding native NP tissue and cells found within the L-pNIPAM-co-DMAc hydrogel itself (Fig 2a,b). No significant difference in the number of caspase 3 immunopositive cells was observed between the different experimental groups at any time point (Fig 2a,b) ($P>0.05$).

3.3. Structural and mechanical characterisation

3.3.1. Scanning electron microscopy

The interior micro scale morphology of NP tissue explants was examined using scanning electron microscopy (SEM) (Fig 3). Native NP cells were visualised embedded within a disorganised fibrous collagen matrix, throughout the 6 week culture duration in media injected control explants (Fig 3). Where MSCs were injected alone clustered cells could be seen following 48 hours which appeared to have migrated following 6 weeks in culture (Fig 3). Injected acellular L-pNIPAM-co-DMAc hydrogel displayed a comparatively uniform interconnecting porous network encapsulated by the surrounding NP tissue following 6 weeks in culture. Where MSCs were incorporated within the L-pNIPAM-co-DMAc hydrogel prior to injection, cells could be seen within the centre of the hydrogel region (Fig 3); a distinction in

the microscale morphology of the interior hydrogel was still evident in comparison to the native surrounding NP tissue following 6 weeks, however integration could be seen at the hydrogel/NP tissue interface with connecting NP tissue fibres penetrating within the outside edges of the hydrogel region (Fig 3).

3.3.2. Dynamic mechanical analysis

MSC injected and hydrogel injected NP tissue explants displayed similar mechanical properties to media injected control explants with no significant difference in the elastic modulus (G'), loss modulus (G'') or tan delta ($\tan\delta$) for any of the experimental groups following 6 weeks in culture (Fig 4a,b,c).

3.3.3. Hydration assessment

The injection of MSCs alone did not significantly alter the hydration degree of NP tissue explants following 48 hours, 4 and 6 weeks in culture, although a significant increase ($P=0.0011$) in the hydration of hMSC injected alone NP tissue explants was observed in comparison to media injected control explants following 2 weeks in culture (Fig 4d). Where acellular L-pNIPAM-co-DMAc hydrogel was injected a significant increase ($P=0.0064$) in the hydration degree was observed in comparison to media injected control explants following 6 weeks in culture (Fig 4d). Where hMSCs were incorporated into L-pNIPAM-co-DMAc hydrogel prior to injection a significant increase in the hydration degree was observed in comparison to media injected control explants following 2 ($P=0.0015$) and 6 ($P=0.0095$) weeks in culture in comparison to control explants (Fig 4d).

423

424 **3.4. Histological evaluation of matrix components**

425 Reduced matrix staining for both proteoglycans, and collagen was observed
426 throughout the 6 week culture period within media injected control NP explants (Fig
427 5). Where MSCs were injected alone, blue staining for proteoglycans was present
428 within and surrounding the cell clusters, although the staining intensity was less than
429 that of the native surrounding NP tissue (Fig 5). Areas of blue staining for collagen
430 were also observed within cell clusters where MSCs had been injected alone,
431 although the majority of cells present within the clusters were negative (red) for
432 collagen staining (Fig 5). Positive blue matrix staining for both proteoglycans and
433 collagen was observed within the acellular L-pNIPAM-co-DMAc hydrogel which had
434 been injected into NP explants, particularly following 4 and 6 weeks (Fig 5). A distinct
435 native NP tissue border, with high intensity collagen staining, was observed
436 surrounding the acellular L-pNIPAM-co-DMAc hydrogel following 48 hours, 2 and 4
437 weeks in culture (Fig 5). Blue positive proteoglycan and collagen producing cells
438 were observed within the L-pNIPAM-co-DMAc hydrogel where hMSCs had been
439 incorporated prior to injection throughout the 6 week culture duration (Fig 3). Native
440 NP tissue directly adjacent to L-pNIPAM-co-DMAc hydrogel with incorporated
441 hMSCs, demonstrated strong intensity staining for both proteoglycans and collagen
442 (Fig 5). A distinct NP tissue border, with high intensity collagen staining, was present
443 surrounding the L-pNIPAM-co-DMAc hydrogel, where MSCs were incorporated,
444 following 48 hours and 2 weeks in culture, however this was subsequently absent
445 with integration of the surrounding NP tissue within the hydrogel observed following
446 4 and 6 weeks in culture (Fig 5).

447

448 **3.5. Immunohistochemical evaluation of cell phenotype**

449 Immunohistochemistry was used to assess the expression and localisation of the NP
450 matrix markers collagen type II, aggrecan and chondroitin sulphate within MSCs,
451 both in monolayer and following injection into NP tissue explants, as well as within
452 native NP cells within the explant tissue (Fig 6). Collagen type II, aggrecan and
453 chondroitin sulphate was expressed by all native NP cells found with control,
454 acellular L-pNIPAM-co-DMAc injected, hMSC only injected and hMSC incorporated
455 within L-pNIPAM-co-DMAc injected NP tissue explants, throughout the 6 week
456 culture duration (Fig 6). Immunopositive cells for collagen type II, aggrecan and
457 chondroitin sulphate were identified surrounding the acellular L-pNIPAM-co-DMAc
458 hydrogel following 48 hours, 2 and 4 weeks in culture, with some immunopositive
459 native NP cells for collagen type II, aggrecan and chondroitin sulphate observed
460 within the acellular L-pNIPAM-co-DMAc hydrogel following 6 weeks in culture (Fig 6).
461 Monolayer MSCs extracted from culture prior to injection into NP tissue explants
462 showed no immunopositivity for aggrecan, with low levels of immunopositivity for
463 chondroitin sulphate (average 52% range 50-55%) and collagen type II (average
464 17% range 14-20%) (Suppl Fig 1). Immunopositive cellular and matrix staining for
465 collagen type II, aggrecan and chondroitin sulphate was observed within the vicinity
466 of the cell clusters where hMSCs had been injected alone, from 48 hours to 6 weeks
467 in culture (Fig 6). Intense matrix staining and positive cellular staining for collagen
468 type II, aggrecan and chondroitin sulphate was observed within the L-pNIPAM-co-
469 DMAc hydrogel where MSCs had been incorporated prior to injection (Fig 6). NP
470 tissue with high intensity matrix staining for collagen type II and chondroitin sulphate
471 was present integrating within the L-pNIPAM-co-DMAc hydrogel where MSCs had

been incorporated prior to injection, following 6 weeks in culture (Fig 6). All IgG control sections for collagen type II, aggrecan and chondroitin sulphate showed no immunopositivity (suppl Fig 1).

3.6. Mechanical Characterisation of L-pNIPAM-co-DMAc hydrogel injected Whole Bovine IVD.

Whole bovine IVDs subjected to loading simulating a short period of walking demonstrated a different mechanical response depending on the treatment regime of the disc. When differences in disc size were accounted for and outliers excluded healthy discs had 1.88 times higher stiffness (24.3 to 12.9 MPa) (Fig7A), 80% lower strain (0.54% to 2.7%) (Fig 7B) and 2.8 times greater energy dissipation (2.12 to 0.76 J/cycle) (Fig 7C) compared to discs that had undergone collagenase digestion, with $P < 0.001$ in each case when outliers were accounted for (Fig 7). Discs subjected to collagenase digestion could be seen in 6 out of 10 discs to display clear digestion of the IVD (Fig 7) with alteration to mechanical properties, however 4 discs which were injected with collagenase failed to show evidence of digestion (no voids visible) and thus were removed from the statistical analysis and showed as red outliers (Fig 7). Discs subjected to the same collagenase treatment process following observation of clear evidence of digestion morphologically were subsequently injected with L-pNIPAM-co-DMAc hydrogel, these discs demonstrated a complete recovery of disc stiffness, displaying only non-significant ($P > 0.05$) differences from healthy disc stiffness (24.3 to 26.4 MPa) (Fig 7A) and strain values (0.54% to 0.5%) (Fig 7B). However there was no recovery of the discs ability to dissipate energy (Fig7C), with hydrogel injected discs dissipating less energy than any other test group (0.40 J/cycle), significantly ($P < 0.001$) lower than even collagenase digested discs (Fig 7c). Discs injected with hydrogel containing green dye could be clearly identified

macroscopically (Fig 7D,E) and microscopically were shown to fill the fissures formed via collagenase digestion (Fig 7F,G).

4. Discussion

4.1. Evaluation of biological performance to act as a cell delivery vehicle.

The clinical translation of hydrogels specifically developed for the delivery of regenerative cells to the IVD is dependent on several requirements: that they can be administered by a minimally invasive procedure that delivers the required cell population without detrimental effects to both the implanted cells and surrounding tissues during delivery. That they are biocompatible and thus support the viability of delivered cells and native cell populations. The hydrogel should facilitate cellular migration to aid in the integration with surrounding tissue to prevent biomaterial extrusion. Finally, the hydrogel should support and promote the differentiation of delivered MSCs into biologically functional NP like cells in order to repair and regenerate a matrix akin to native NP tissue.

4.1.2. Minimally Invasive delivery of L-pNIPAM-co-DMAC hydrogel

In our previous *in vitro* studies we have demonstrated that hMSC could be incorporated into liquid L-pNIPAM-co-DMAc hydrogel, injected through a narrow 26-gauge needle before solidification at 37°C with no detriment to cell viability [23,33]. Here, acellular L-pNIPAM-co DMAc hydrogel was injected through the AF into collagenase digested bovine IVD via 26-gauge needle injection. The hydrogel was maintained within the disc during mechanical loading and shown histologically to infiltrate micro and macro fissures akin to those which could occur during IVD

degeneration. The selected needle diameter is an important design consideration which is often dictated by the viscosity of the biomaterial being injected [34]. It is generally accepted that the needle diameter should be as narrow as possible to avoid structural and mechanical damage to surrounding tissues during injection. However decreasing the needle diameter for viscous biomaterials increases injection pressures which can increase shear forces on cells reducing cell viability [34,35]. The low viscosity (0.97MPas at 54°C) [23] of the L-pNIPAM-co-DMAC liquid hydrogel, enabled its injection with incorporated hMSCs into NP tissue explants with no loss in viability. The minimally invasive route demonstrated here offers significant advantage over previously developed hydrogels implanted into IVD tissue where nucleotomy was required to create a void for the biomaterial to occupy [13-16,36], or large diameter surgical implanting tools were used [37]. Moreover, the synthetic route utilised, which exploits the thermal phase transition of a fully reacted polymer in the liquid state, offers rapid solidification at 37°C. This maintains the L-pNIPAM-co-DMAC hydrogel and incorporated hMSCs within the injection site, whilst avoiding the need for additional implantation devices to initiate *in situ* polymerisation such as those proposed for photopolymerised hydrogels [15,25,34].

4.1.3. Biocompatibility of L-pNIPAM-co-DMAC hydrogel.

The biocompatibility of delivered hMSCs is essential if the repopulation of cells for the long term recovery and regeneration of a functional NP matrix is to be a viable therapeutic option in the treatment of IVD degeneration. In agreement with previous studies [17,20,38-42], excellent viability across all time points and all treatment regimes were observed. However, despite mimicking the hypoxic disc microenvironment, it should be noted that the culture conditions used in this study do not completely reflect that of the native IVD in terms of a mechanically loaded

environment [43] and low nutrient supply [44]. Moreover, the degenerate IVD is an extremely hostile biological environment with increased production of matrix degrading enzymes [6] and pro-inflammatory cytokines [8,9] which may affect viability *in vivo*. Future investigations to ascertain the survival of delivered MSCs within such conditions is paramount to the clinical translation of this kind of therapy. However the survival of MSCs incorporated within the L-pNIPAM-co-DMAc hydrogel, is extremely promising since the use of the hydrogel as a delivery system also provides the opportunity to simultaneously deliver antagonists of catabolic mediators if required.

4.1.4. Integration of L-pNIPAM-co-DMAc hydrogel.

The infiltration of native NP cells, demonstrated in both acellular and hMSC incorporated within the L-pNIPAM-co-DMAc hydrogel injected into NP explants, is particularly important to aid in scaffold integration with the surrounding NP tissue, to restore optimum mechanical function and prevent issues such as biomaterial extrusion [14,45]. Integration of L-pNIPAM-co-DMAc hydrogel with surrounding NP tissue was particularly evident in this study, with deposited matrix penetrating within the hydrogel/tissue interface shown histologically and using SEM. Despite initial fibrous encapsulation observed surrounding the hydrogel following 4 weeks in acellular L-pNIPAM-co-DMAc hydrogel injected NP tissue explants, it is hypothesised that dynamic culture under mechanical load would promote and accelerate the hydrogel tissue integration, as dynamic compressive mechanical loading has been shown to promote NP matrix biosynthesis [46], increase NP cell metabolism [46,47] and promote proliferation and differentiation of MSCs into NP-like cells [48,49].

4.1.5. Differentiation of MSCs following Injection into NP tissue explants

In agreement with previous studies [17], where MSCs were injected alone into NP tissue explants, the cells were maintained within clusters at the vicinity of the injection site for up to 4 weeks, although migration was evident following 6 weeks in culture. Migration and differentiation of these cells into NP like cells is essential for efficacious NP matrix repair. Here MSCs injected alone were shown to produce NP matrix components collagen type II, aggrecan and chondroitin sulphate. The deposition of this matrix was localised immunohistochemically to the clusters of MSCs visualised, indicating that the MSCs themselves were responsible for the matrix synthesis; this is in agreement with previous studies [17,20,39]. Despite this, a major concern for the clinical translation of stem cell therapy for the treatment of IVD degeneration is a lack of control over the differentiation capacity of these cells following injection into nucleus pulposus tissue [27]. In addition, the location of these cells following injection is crucial since MSC leakage followed by undesirable bone formation has been reported previously as a potential side effect of this therapeutic strategy [26]. The incorporation of MSCs within the L-pNIPAM-co-DMAc hydrogel during the liquid phase for delivery, is advantageous as it ensures the interconnecting porous hydrogel network is able to assemble around the cells. This ensures that in the initial weeks following injection that the cells are maintained within the injection site and that the microenvironment of the hydrogel itself will be the first structural influence on the differentiation capacity of the MSCs. This gives a greater potential control over the differentiation and location of the delivered regenerative cells. We have previously demonstrated *in vitro* that MSCs incorporated into L-pNIPAM-co-DMAc hydrogel and cultured under hypoxic conditions induces differentiation of MSCs into NP like cells without the need for additional

chondrogenic inducing medium or growth factors [23]. Here, we have shown that cells incorporated into L-pNIPAM-co-DMAc hydrogel and injected into NP explants were shown to produce NP matrix components: collagen type II; aggrecan and chondroitin sulphate. We are unable to ascertain whether the matrix deposition itself is from the delivered MSCs or native NP cells, it is most likely to be a combination of both since positive cells and deposited matrix which compositionally reflects native NP tissue, was observed both within the hydrogel itself and surrounding the hydrogel/tissue interface. Thus the translation of our previous *in vitro* results within an *ex vivo* NP tissue explant model demonstrated here, offers significant promise for the efficacy of this therapeutic strategy in the delivery of MSCs for the repair and regeneration of the NP as a future treatment of IVD degeneration. A short coming of the current study is that commercial MSCs were utilised, thus future investigations should be conducted to assess the differentiation of MSCs from a large cohort of human patients to determine patient variability and age of patients which can be utilised for such a therapy.

4.2. Evaluation of mechanical properties to act as a support scaffold:

The NP is regarded as a viscoelastic material, exhibiting both fluid and solid like behaviours [50]. It has been well documented that the viscoelasticity of NP tissue changes with ageing and degeneration, exhibiting a more 'solid-like' than 'fluid-like' behavior, reflected by a decreased $\tan\delta$ [51]. One of the hallmarks of IVD degeneration is a reduction in the overall proteoglycan content [7] resulting in reduced tissue hydration [4,52,53]. The injection of a hydrogel biomaterial, defined as a 3D hydrated crosslinked polymeric network, has therefore been hypothesised as an appealing strategy to restore NP tissue hydration and thus potentially regain

some of the viscoelastic NP material properties [54,55]. The significant increase in hydration degree of NP tissue explants following 6 weeks where acellular and hMSC incorporated L-pNIPAM-co-DMAc hydrogel was injected, provides promising evidence to suggest that the L-pNIPAM-co-DMAc hydrogel material itself is compositionally advantageous to the overall NP tissue hydration. The benefits of which would be even more apparent within degenerate tissue. Despite the increased hydration degree no significant difference in the G' , G'' or the $\tan\delta$ were observed regardless of whether hMSCs or L-pNIPAM-co-DMAc hydrogel were injected. This is likely due to the fact that the NP tissue explant controls used in this study were not experimentally manipulated to be degenerate; thus the fact that there is no statistical difference in the viscoelastic parameters assessed between the different experimental groups, indicates that both hMSC and L-pNIPAM-co-DMAc hydrogel injected NP tissue explants display similar biomechanical properties to native NP tissue. A limitation that should be considered however is that in this study the NP tissue explants were statically cultured within a semi-constrained Perspex ring culture system, therefore the biomechanical properties of the explant NP tissue is likely to be different from native NP tissue found within the body[49,56].

Loading of whole bovine collagenase digested IVDs injected with L-pNIPAM-co-DMAc hydrogel, demonstrated a significant recovery of structural properties, completely regaining pre-digested levels of disc stiffness. The full recovery of disc mechanical response following hydrogel injection, shown in this study, is a highly promising result, providing supporting evidence that the hydrogel could offer a significant and near immediate structural benefit to degenerate IVDs.

Unfortunately modelling degeneration in the disc is problematic, and whilst collagenase digestion targets the collagen matrix within the disc the proteoglycan

components would still be non-digested. However as the collagen matrix forms the interconnecting network which holds the proteoglycan proteins in place, it was observed that the majority of collagenase digested discs generated large voids both macro and microscopically mimicking at least in part morphological features of degeneration. A limitation of the current study was that digestion of the discs using collagenase did not always induce digestion (4 out of 10 discs) and these samples failed to show any mechanical response. Therefore when performing the hydrogel injection following collagenase digestion, discs were carefully examined to ensure voids were visible prior to hydrogel insertion. Following loading, histological analysis demonstrated collagenase digested voids were filled with hydrogel, in all discs investigated.

The reduced stiffness of collagenase digested discs and subsequent recovery following the introduction of the L-pNIPAM-co-DMAc hydrogel system may initially seem counter intuitive. Damage and degeneration of the NP expected to reduce 'fluid-like' behaviour of the disc in favour of stiffer, 'solid-like' behaviour [4,51,53]. The collagenase digestion process resulted in the creation of voids or fissures within the NP, as evidenced by macro and microscopic imaging of tissues, but minimal structural damage to the AF. The result, *in vitro*, is a disc which maintains its original height yet contains easily compressible voids, resulting in reduced bulk stiffness. More significant breakdown of disc tissue or full or partial excision of the disc nucleus, particularly when combined with long term, continuous pressure on the IVD *in vitro* [57] is liable to compress voids, reducing disc height and resulting in a thin disc of mostly AF tissue, which is stiffer than that of the NP [58]. This non-linear variation in disc stiffness with degeneration grade has previously been observed in torsion, flexion and bending [59,60]. When comparing stiffness of moderately degenerate

669 discs compressed *in vitro* to degenerate discs *in vivo* it may be more accurate to look
670 at the results in terms of potential to lose disc height, an important biomarker of disc
671 degeneration [23-27].

672 Interestingly, significantly lower energy dissipation was observed in groups injected
673 with the needle: sham injected; collagenase digested; and collagenase digestion
674 followed by hydrogel injection, compared with healthy whole bovine IVDs. **In contrast**
675 **Michalek & Iatridis, (2012) observed no apparent difference in pressurization testing**
676 **following needle puncture of bovine motion segments [61]. Interestingly however the**
677 **study by Michalek & Iatridis (2012) induced a 10mm deep defect within the AF which**
678 **would not have lead to puncture of the NP unlike the current study where needle**
679 **puncture was performed to the centre of the disc and thus into the NP region [61].**
680 **Furthermore the loading rate investigated by Michalek & Iatridis, (2012) was**
681 **considerably lower (0.1Hz) compared to the 2Hz used in the present study [61]. In**
682 **the present study these dynamic parameters were selected to mimic that of walking**
683 **in the human spine to enable a functional assessment of the treatment methods. The**
684 **loss in energy disipation seen in the current study following needle puncture through**
685 **the AF and into the NP together with the results of Carragee *et al.*, 2009, suggests**
686 **that the needle puncture itself in healthy IVDs may be the key initiator of discs losing**
687 **tissue functionality, likely due to a loss in the pressure of the IVD [62]. **However, as****
688 **the degenerate **human** disc **will** already have a reduced energy dissipation capacity**
689 **due to matrix degradation and presence of fissures [51,63,64]. The delivery of the L-**
690 **pNIPAM-co-DMAc hydrogel system via needle injection, is not likely to initiate any**
691 **further loss in energy dissipation but will provide an immediate mechanical and**
692 **clinical benefit in terms of IVD stabilisation, to what is likely to be, at the time of**
693 **patient treatment, a mechanically dysfunctional tissue.**

694 The injection of acellular L-pNIPAM-co-DMAc hydrogel injection did not recover
695 energy dissipation to pre-digested levels; however the energy dissipation
696 functionality is reliant on the unique pressurised environment of the intact IVD [65],
697 therefore it is unlikely that the implantation of a biomaterial alone would provide this
698 biomechanical function immediately. It is hypothesised that over time as the L-
699 pNIPAM-co-DMAc hydrogel integrates with surrounding NP tissue, whilst the
700 delivered MSCs simultaneously repair and regenerate a biologically functioning NP
701 matrix to fill in any potential fissures, that the pressurised environment and energy
702 dissipation function of the IVD will be restored.

703 The mechanical benefit of hydrogel injection within IVDs has been previously
704 reported, including the restoration of the load transmission [36] and re-established
705 disc height maintained over 0.5 million loading cycles within a bovine organ culture
706 model [15], however in both cases, nucleotomy was required for hydrogel
707 implantation and the incorporation and delivery of cells was not investigated.
708 Recently Balkovec *et al.*, 2016 reported the restoration of segmental kinematics to
709 pre injury state in IVDs with disc height loss, following hydrogel injection, within an *ex*
710 *vivo* porcine cervical spine model; however again nucleotomy was required to inject
711 the hydrogel, the incorporation and delivery of cells was not investigated [13] and the
712 immediate mechanical restoration of the hydrogel was not maintained following
713 cyclic loading [14].

714 The development of a biomaterial which offers the ability to safely deliver and
715 differentiate cells, without the use of additional growth factors, as well as providing
716 mechanical stabilisation, has so far not been achieved. Here, we demonstrate that
717 the L-pNIPAM-co-DMAc hydrogel can be delivered by minimally invasive injection
718 into collagenase digested whole bovine IVDs. Where it fills micro and macro fissures,

is maintained within the disc during loading and provides immediate mechanical stabilisation with improved disc stiffness back to non-digested levels, without the need for prior removal of the NP tissue. Future investigations are required to assess the fatigue properties of the hydrogel following prolonged cyclic loading. The promising results displayed here suggest that the L-pNIPAM-co-DMAc hydrogel could provide a treatment strategy which requires a less invasive surgical intervention, in regards to removal of native tissue, which may promote better tissue integration and tissue functionality. Moreover the ability to safely deliver and promote NP differentiation of MSCs within the L-pNIPAM-co-DMAc hydrogel system also provides the opportunity to biologically repair the disc as well as providing mechanical stability.

4.3. Treatment design strategy tailored for stage of degeneration.

Our improved understanding of the underlying pathogenesis of IVD degeneration over recent years and the consequential morphological changes that occur should be conveyed in our treatment design strategies [21,22]. It is possible that clinicians could be presented with a variety of treatment options, both cellular and acellular, in order to deliver the most efficacious, safe and cost effective treatment for the stage of degeneration [21]. Of course clinical translation is reliant on the detection and diagnosis of patients with early to mid-stages of IVD degeneration; however recent advances in quantitative MRI imaging give future promise to this possibility [66]. Future investigations into the survival and differentiation of MSCs within the hostile environment of a severely degenerate IVD are crucial in determining the success of stem cell intervention for these patients. Additionally hydrogel containment and mechanical stability within severely degenerate IVDs, where annular fissures, osteophytes and endplate fractures may be clinically present, must also be

investigated to assess whether hydrogels can offer clinical benefit for late stage IVD degeneration. The results of these investigations, in combination with the design of suitable biomaterials and diagnostic techniques will determine the future possibility of personalized therapies for IVD degeneration.

5. Conclusion

Here, we have investigated the efficacy of a range of treatment options: hMSCS injected alone, acellular L-pNIPAM-co-DMAc and hMSCs incorporated within the L-pNIPAM-co-DMAc hydrogel, injected into bovine NP tissue explants. Demonstrating that hMSCs injected alone or incorporated within the L-pNIPAM-co-DMAc hydrogel are able to differentiate and produce NP matrix components, thus providing compelling evidence in support of cell delivery for NP matrix repair. Additionally we have demonstrated immediate mechanical stabilisation with the injection of acellular L-pNIPAM-co-DMAc hydrogel into whole bovine IVDs, demonstrating a potential clinical benefit even in the absence of cells. The delivery of the L-pNIPAM-co-DMAc hydrogel system via minimally invasive 26 gauge needle injection and its ability to fill micro fissures, without the removal of the existing NP tissue, provides the opportunity to target symptomatic patients in early to mid-stages of degeneration. The use of a combined cellular and mechanical repair approach is particularly promising since it is hypothesised that the L-pNIPAM-co-DMAc hydrogel, could restore disc height, thus providing immediate pain relief, whilst delivery of MSCs provides gradual regeneration.

5. Author contributions

AAT performed the majority of the laboratory work (except for the mechanical testing of whole bovine IVDs), data analysis and statistical analysis, contributed to study

design and drafted the manuscript. GD performed the laboratory work and data analysis for the mechanical testing of whole bovine IVDs and helped draft the manuscript. LV assisted in the experimental set up of bovine NP tissue explants and critically revised the manuscript. NS and GC participated in the design and coordination of the mechanical testing experiments on whole bovine IVDs, aided in the analysis of data and critically revised the manuscript. CS and CLLM conceived the study, participated in its design and coordination, aided in the analysis of data, secured funding and critically revised the manuscript. All authors read and approved the final manuscript.

6. Acknowledgements

We would like to offer kind thanks to the Biomolecular Sciences Research Centre, Sheffield Hallam University and Manchester Metropolitan University for PhD studentships. The Authors wish to thank the EPSRC (EP/H000275/1 and EP/1016473/1) for funding the initial work and the Daphne Jackson trust for supporting Dr Vickers as a Daphne Jackson Fellow.

7. Disclosure

No conflicts of interest to declare.

Figure Legends:

Figure 1: Photomicrographs of haematoxylin & eosin stain, Hoechst staining and green fluorescent protein CFSE positive cells (shown inset for hMSC and hMSC + Hy NP tissue explants) in the injection sites of bovine nucleus pulposus tissue following 48 hours, 2, 4 and 6 weeks in culture. Magnified images of native NP cells,

790 stained with Hoechst, surrounding acellular hydrogel, shown inset to aid visualisation.
791 White arrows on acellular Hy images indicate cells, black arrows on H&E images
792 indicate hydrogel/tissue interface, red arrows on H&E images for hMSC + Hy
793 indicate cells within hydrogel. Media injected control tissue (Control), CFSE positive
794 hMSC injected alone (Injected hMSC), L-pNIPAM-co-DMAc hydrogel injected
795 without cells (Acellular Hy) and hMSC incorporated into L-pNIPAM-co-DMAc
796 hydrogel injected (hMSC+ Hy). *Scale bar = 50 μ m or 100 μ m.*

797 **Figure 2:** Immunohistochemical detection of caspase 3 to assess cell viability after
798 48 hours, 2, 4 and 6 weeks in culture. Percentage immunopositivity was calculated
799 (A). Photomicrographs representative of caspase 3 immunopositivity in tissue
800 explants at 48 hours and 6 weeks post injection (B). Back arrows indicate positively
801 stained cells and white arrows indicate negatively stained cells. *Scale bar = 100 μ m.*

802 **Figure 3:** Scanning Electron Microscopy (SEM) of media injected control (Control),
803 hMSC injected alone (hMSC), Acellular L-pNIPAM-co-DMAc hydrogel injected
804 (Acellular Hy) and hMSC incorporated within L-pNIPAM-co-DMAc hydrogel injected
805 (hMSC + Hy) NP tissue explants following 48 hours and 6 weeks in culture. Enlarged
806 images of native NP cells (control), hMSCs (hMSCs injected alone) and cells within
807 hydrogel region (Acell 6 weeks, hMSC + Hy 48 hours and 6 weeks) shown inset for
808 visualisation. White arrows indicate native NP cells within Control NP explants and
809 presence of hMSCs within hMSC injected alone NP explants. Blue arrows indicate
810 NP tissue/hydrogel interface, demonstrating integration of hydrogel with surrounding
811 NP tissue. *Scale bar 50 μ m.*

812 **Figure 4:** Mechanical Analysis of bovine explant NP tissue using dynamic
813 mechanical analysis (A,B,C). (A) Elastic modulus (G'), (B) loss modulus (G'') and (C)

814 Tan Delta ($\tan\delta$) at 2.5Hz after 6 weeks in culture. (D) Calculated hydration degree
815 of bovine explant tissue throughout 6 weeks in culture. Media injected control (con),
816 hMSC injected alone (hMSC), acellular L-pNIPAM-co-DMAc injected (Acell Hy) and
817 hMSC incorporated into L-pNIPAM-co-DMAc injected (hMSC + Hy). (*) Indicates
818 statistical significance compared to controls at each timepoint (D) ($*p = \leq 0.05$).

819 **Figure 5:** Histological evaluation of bovine NP tissue explants using Alcian blue (AB)
820 for proteoglycan deposition and Masson trichrome (MT) for collagen deposition after
821 48 hours, 2, 4 and 6 weeks in culture. Media injected control tissue (control), hMSCs
822 injected alone (hMSC), Acellular L-pNIPAM-co-DMAc injected (Acellular Hy) and
823 hMSCs incorporated within L-pNIPAM-co-DMAc hydrogel injected (hMSC + Hy).
824 Black arrows indicate positively stained cells, red arrows indicate negatively stained
825 cells and orange arrows indicate hydrogel/NP tissue interface. Magnified images of
826 representative cells shown inset for visualisation. *Scale bar = 100 μ m.*

827 **Figure 6:** Immunohistochemical detection of NP matrix markers collagen type II,
828 aggrecan and chondroitin sulphate in bovine NP tissue explants. Representative
829 photomicrographs after 48 hours, and 6 weeks in culture. Black arrows demonstrate
830 positively stained cells and green arrows demonstrate negatively stained cells.
831 Enlarged immunopositive cells shown inset for visualisation. *Scale bar = 100 μ m.*

832 **Figure 7:** Mechanical analysis of whole bovine IVDs that were healthy, stabbed with
833 21G needle (sham), collagenase digested or collagenase digested followed by
834 hydrogel injection (hydrogel). Measured parameters include: (A) Young's Modulus,
835 (B) % Strain and (C) Energy Dissipation. Four discs (red) from the digested group
836 demonstrated young's modulus and strain behaviour similar to sham injected
837 suggesting collagenase injection had been insufficient and this was supported by the

lack of morphological evidence of collagenase digestion in these discs, thus were marked as outliers but Energy Dissipation was in line with other needle punctured discs. All replicates have been shown with outliers marked in red to demonstrate clearly the spread of replicates. Median values indicated do not include outliers within digested group. (*) Indicates significant differences between experimental groups ($p \leq 0.05$). (D) Representative macroscopic image of whole bovine IVD following collagenase digestion (average IVD diameter 30mm). (E) Representative macroscopic image following collagenase digestion and hydrogel injection, with a green food dye incorporated within the hydrogel to aid visualisation. (F, G) Microscopic images stained with haematoxylin and eosin of whole IVD following collagenase digestion, hydrogel injection and mechanical loading. Scale bar 1000 μ m, 200 μ m.

References

- [1] Hoy DG, Smith E, Cross M, Sanchez-Riera L, Blyth FM, Buchbinder R, Woolf AD, Driscoll T, Brooks P, March LM. Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the global burden of disease 2010 study and the next steps forward. *Ann Rheum Dis* (2015);74:4-7.
- [2] Cheung KM, Karppinen J, Chan D, Ho DW, Song YQ, Sham P, Cheah KS, Leong JC, Luk KD. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. *Spine (Phila Pa 1976)* (2009);34:934-940.
- [3] Livshits G, Popham M, Malkin I, Sambrook PN, Macgregor AJ, Spector T, Williams FM. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study. *Ann Rheum Dis* (2011);70:1740-1745.

- 865 [4] Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement
866 of the extracellular matrix. *Spine* (2004);29:2691-2699.
- 867 [5] Schultz A, Warwick D, Berkson M, Nachemson A. Mechanical properties of
868 human lumbar spine motion segments—Part I: Responses in flexion, extension,
869 lateral bending, and torsion. *J Biomech Eng* (1979);101:46-52.
- 870 [6] Le Maitre C, Pockert A, Buttle D, Freemont A, Hoyland J. Matrix synthesis and
871 degradation in human intervertebral disc degeneration. *Biochem Soc Trans*
872 (2007);35:652.
- 873 [7] Cs-Szabo G, Ragasa-San Juan D, Turumella V, Masuda K, Thonar EJ, An HS.
874 Changes in mRNA and protein levels of proteoglycans of the anulus fibrosus and
875 nucleus pulposus during intervertebral disc degeneration. *Spine (Phila Pa 1976)*
876 (2002);27:2212-2219.
- 877 [8] Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF
878 in matrix degradation in the intervertebral disc. *Rheumatology (Oxford)*
879 (2008);47:809-814.
- 880 [9] Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in
881 degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha
882 expression profile. *Arthritis Res Ther* (2007);9:R77.
- 883 [10] Le Maitre CL, Freemont AJ, Hoyland JA. Accelerated cellular senescence in
884 degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral
885 disc degeneration. *Arthritis Res Ther* (2007);9:R45.
- 886 [11] Urban JP, McMullin JF. Swelling pressure of the lumbar intervertebral discs:
887 influence of age, spinal level, composition, and degeneration. *Spine (Phila Pa 1976)*
888 (1988);13:179-187.
- 889 [12] Olmmarker K, Rydevik B. Single-versus double-level nerve root compression: an
890 experimental study on the porcine cauda equina with analyses of nerve impulse
891 conduction properties. *Clin Orthop* (1992);279:35-39.

- 892 [13] Balkovec C, Vernengo AJ, McGill SM. Disc height loss and restoration via
893 injectable hydrogel influences adjacent segment mechanics in-vitro. Clin Biomech
894 (2016);36:1-7.
- 895 [14] Balkovec C, Vernengo AJ, Stevenson P, McGill SM. Evaluation of an injectable
896 hydrogel and polymethyl methacrylate in restoring mechanics to compressively
897 fractured spine motion segments. *Spine J.* (2016);11:1404-1412.
- 898 [15] Schmocker A, Khoushabi A, Frauchiger DA, Gantenbein B, Schizas C, Moser C,
899 Bourban P, Pioletti DP. A photopolymerized composite hydrogel and surgical
900 implanting tool for a nucleus pulposus replacement. Biomaterials (2016);88:110-119.
- 901 [16] Miles D, Mitchell E, Kapur N, Beales P, Wilcox R. Peptide: glycosaminoglycan
902 hybrid hydrogels as an injectable intervention for spinal disc degeneration. *J. Mater.*
903 *Chem. B* (2016);4:3225-3231.
- 904 [17] Le Maitre CL, Baird P, Freemont AJ, Hoyland JA. An in vitro study investigating
905 the survival and phenotype of mesenchymal stem cells following injection into
906 nucleus pulposus tissue. *Arthritis Res Ther.* (2009);11:R20.
- 907 [18] Kim KW, Lim TH, Kim JG, Jeong ST, Masuda K, An HS. The origin of
908 chondrocytes in the nucleus pulposus and histologic findings associated with the
909 transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus
910 in intact rabbit intervertebral discs. Spine (Phila Pa 1976) (2003);28:982-990.
- 911 [19] Orozco L, Soler R, Morera C, Alberca M, Sanchez A, Garcia-Sancho J.
912 Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot
913 study. Transplantation (2011);92:822-828.
- 914 [20] Zhang Y, Guo X, Xu P, Kang L, Li J. Bone mesenchymal stem cells transplanted
915 into rabbit intervertebral discs can increase proteoglycans. Clin Orthop
916 2005;430:219-226.
- 917 [21] Thorpe A, Sammon C, Le Maitre C. Cell or Not to Cell'that is the Question: For
918 Intervertebral Disc Regeneration. *J Stem Cell Res Dev* (2015);2.

919 [22] Le Maitre CL, Binch AL, Thorpe AA, Hughes SP. Degeneration of the
 920 intervertebral disc with new approaches for treating low back pain. *J Neurosurg Sci*
 921 2015;59:47-61.

922 [23] Thorpe A, Boyes V, Sammon C, Le Maitre C. Thermally triggered injectable
 923 hydrogel, which induces mesenchymal stem cell differentiation to nucleus pulposus
 924 cells: Potential for regeneration of the intervertebral disc. *Acta Biomater*
 925 (2016);36:99-111.

926 [24] Richardson SM, Hughes N, Hunt JA, Freemont AJ, Hoyland JA. Human
 927 mesenchymal stem cell differentiation to NP-like cells in chitosan–glycerophosphate
 928 hydrogels. *Biomaterials* (2008);29:85-93.

929 [25] Kumar D, Gerges I, Tamplenizza M, Lenardi C, Forsyth NR, Liu Y. Three-
 930 dimensional hypoxic culture of human mesenchymal stem cells encapsulated in a
 931 photocurable, biodegradable polymer hydrogel: A potential injectable cellular product
 932 for nucleus pulposus regeneration. *Acta Biomater* (2014);8:3463-3467.

933 [26] Vadalà G, Sowa G, Hubert M, Gilbertson LG, Denaro V, Kang JD. Mesenchymal
 934 stem cells injection in degenerated intervertebral disc: cell leakage may induce
 935 osteophyte formation. *J Tissue Eng Regen Med* (2012);6:348-355.

936 [27] Acosta Jr FL, Metz L, Adkisson IV HD, Liu J, Carruthers-Liebenberg E, Milliman
 937 C, Maloney M, Lotz JC. Porcine intervertebral disc repair using allogeneic juvenile
 938 articular chondrocytes or mesenchymal stem cells. *Tissue Eng Part A*
 939 (2011);17:3045-3055.

940 [28] Serhan H, Mhatre D, Defossez H, Bono CM. Motion-preserving technologies for
 941 degenerative lumbar spine: The past, present, and future horizons. *SAS J*
 942 (2011);5:75-89.

943 [29] Pelletier M, Walsh W, South N. Nucleus replacement. *Biomater*
 944 (2011);171:e190.

945 [30] Holm S, Holm AK, Ekstrom L, Karladani A, Hansson T. Experimental disc
 946 degeneration due to endplate injury. *J Spinal Disord Tech* (2004);17:64-71.

- 947 [31] Michalek AJ, Buckley MR, Bonassar LJ, Cohen I, Iatridis JC. The effects of
948 needle puncture injury on microscale shear strain in the intervertebral disc annulus
949 fibrosus. *Spine J* (2010);10:1098-1105.
- 950 [32] Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the
951 pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther*
952 (2005);7:R732-R745.
- 953 [33] Thorpe AA, Creasey S, Sammon C, Le Maitre CL. Hydroxyapatite nanoparticle
954 injectable hydrogel scaffold to support osteogenic differentiation of human
955 mesenchymal stem cells. *Eur Cell Mater* (2016);32:1-23.
- 956 [34] Kumar D, Lyness AM, Gerges I, Lenardi C, Forsyth NR, Liu Y. Stem Cell
957 Delivery with Polymer Hydrogel for Treatment of Intervertebral Disc Degeneration:
958 from 3D culture to design of the delivery device for minimally invasive therapy. *Cell*
959 *Transplant* (2016);25 (12):2213-2220.
- 960 [35] Amer MH, White LJ, Shakesheff KM. The effect of injection using narrow-bore
961 needles on mammalian cells: administration and formulation considerations for cell
962 therapies. *J Pharm Pharmacol* (2015);67:640-650.
- 963 [36] Zhou Z, Gao M, Wei F, Liang J, Deng W, Dai X, Zhou G, Zou X. Shock
964 absorbing function study on denucleated intervertebral disc with or without hydrogel
965 injection through static and dynamic biomechanical tests in vitro. *Biomed Res Int*
966 (2014);2014:461724.
- 967 [37] Li Z, Lamg G, Chen X, Sacks H, Mantzur C, Tropp U, Mader KT, Smallwood TC,
968 Sammon C, Richards G, Alini M and Grad S. Polyurethane scaffold with in situ
969 swelling capacity for nucleus pulposus replacement. *Biomaterials* (2016); 84: 196-
970 209.
- 971 [38] Hiyama A, Mochida J, Iwashina T, Omi H, Watanabe T, Serigano K, Tamura F,
972 Sakai D. Transplantation of mesenchymal stem cells in a canine disc degeneration
973 model. *J Orthop Res* (2008);26:589-600.

974 [39] Sakai D, Mochida J, Iwashina T, Hiyama A, Omi H, Imai M, Nakai T, Ando K,
975 Hotta T. Regenerative effects of transplanting mesenchymal stem cells embedded in
976 atelocollagen to the degenerated intervertebral disc. *Biomaterials* (2006);27:335-345.

977 [40] Malonzo C, Chan S, Kabiri A, Eglin D, Grad S, Bonél H, Benneker L,
978 Gantenbein-Ritter B.. A papain-induced disc degeneration model for the assessment
979 of thermo-reversible hydrogel–cells therapeutic approach. *J Tissue Eng Regen Med*
980 (2015);9:E167-E176.

981 [41] Crevensten G, Walsh AJ, Ananthakrishnan D, Page P, Wahba GM, Lotz JC,
982 Berven S. Intervertebral disc cell therapy for regeneration: mesenchymal stem cell
983 implantation in rat intervertebral discs. *Ann Biomed Eng* (2004);32:430-434.

984 [42] Mwale F, Wang HT, Roughley P, Antoniou J, Haglund L. Link N and
985 mesenchymal stem cells can induce regeneration of the early degenerate
986 intervertebral disc. *Tissue Eng Part A* (2014);20:2942-2949.

987 [43] Neidlinger-Wilke C, Galbusera F, Pratsinis H, Mavrogonatou E, Mietsch A,
988 Kletsas D, Wilke H. Mechanical loading of the intervertebral disc: from the
989 macroscopic to the cellular level. *Eur Spine J*(2014);23:333-343.

990 [44] Urban JP, Smith S, Fairbank JC. Nutrition of the intervertebral disc. *Spine*
991 (2004);29:2700-2709.

992 [45] Reitmaier S, Kreja L, Gruchenberg K, Kanter B, Silva-Correia J, Oliveira JM,
993 Reis RL, Perugini V, Santin M, Ignatius A, Wilke HJ. In vivo biofunctional evaluation
994 of hydrogels for disc regeneration. *Eur Spine J* (2014);23:19-26.

995 [46] Fernando HN, Czamanski J, Yuan T, Gu W, Salahadin A, Huang CC.
996 Mechanical loading affects the energy metabolism of intervertebral disc cells. *J*
997 *Orthop Res* (2011);29:1634-1641.

998 [47] Iatridis JC, MacLean JJ, Roughley PJ, Alini M. Effects of mechanical loading on
999 intervertebral disc metabolism in vivo. *J Bone Joint Surg Am* (2006);88 Suppl 2:41-
1000 46.

1001 [48] Dai J, Wang H, Liu G, Xu Z, Li F, Fang H. Dynamic compression and co-culture
 1002 with nucleus pulposus cells promotes proliferation and differentiation of adipose-
 1003 derived mesenchymal stem cells. *J Biomech* (2014);47:966-972.

1004 [49] Gantenbein B, Illien-Jünger S, CW Chan S, Walser J, Haglund L, J Ferguson S,
 1005 C Iatridis J, Grad.S. Organ culture bioreactors–platforms to study human
 1006 intervertebral disc degeneration and regenerative therapy. *Curr Stem Cell Res Ther*
 1007 (2015);10:339-352.

1008 [50] Iatridis JC, Weidenbaum M, Setton LA, Mow VC. Is the nucleus pulposus a solid
 1009 or a fluid? Mechanical behaviors of the nucleus pulposus of the human intervertebral
 1010 disc. *Spine* (1996);21:1174-1184.

1011 [51] Iatridis JC, Setton LA, Weidenbaum M, Mow VC. Alterations in the mechanical
 1012 behavior of the human lumbar nucleus pulposus with degeneration and aging.
 1013 (1997);15:318-322.

1014 [52] Roughley PJ, Melching LI, Heathfield TF, Pearce RH, Mort JS. The structure
 1015 and degradation of aggrecan in human intervertebral disc. *J Orthop Res*
 1016 (2006);15:326-332.

1017 [53] Boxberger JI, Sen S, Yerramalli CS, Elliott DM. Nucleus pulposus
 1018 glycosaminoglycan content is correlated with axial mechanics in rat lumbar motion
 1019 segments. *J Orthop Res* (2006);24:1906-1915.

1020 [54] Silva-Correia J, Gloria A, Oliveira MB, Mano JF, Oliveira JM, Ambrosio L, Reis
 1021 RL. Rheological and mechanical properties of acellular and cell-laden methacrylated
 1022 gellan gum hydrogels. *J Biomed Mater Res A* (2013);101:3438-3446.

1023 [55] Silva-Correia J, Oliveira JM, Caridade S, Oliveira JT, Sousa R, Mano J, Reis R.
 1024 Gellan gum-based hydrogels for intervertebral disc tissue-engineering applications. *J*
 1025 *Tissue Eng Regen Med* (2011);5:e97-e107.

1026 [56] van Dijk BG, Potier E, Ito K. Long-term culture of bovine nucleus pulposus
 1027 explants in a native environment. *Spine J* (2013);13:454-463.

1028 57]. Sato K, Kikuchi S, Yonezawa T. In vivo intradiscal pressure measurement in
1029 healthy individuals and in patients with ongoing back problems. *Spine*
1030 (1999);24:2468.

1031 [58]. Périé D, Korda D, Iatridis JC. Confined compression experiments on bovine
1032 nucleus pulposus and annulus fibrosus: sensitivity of the experiment in the
1033 determination of compressive modulus and hydraulic permeability. *J Biomech*
1034 (2005);38:2164-2171.

1035 59]. Adams MA, Dolan P, Hutton WC. The stages of disc degeneration as revealed
1036 by discograms. *J Bone Joint Surg Br* (1986);68:36-41.

1037 [60]. Frobin W, Brinckmann P, Kramer M, Hartwig E. Height of lumbar discs
1038 measured from radiographs compared with degeneration and height classified from
1039 MR images. *Eur Radiol* (2001);11:263-269.

1040 [61]. Michalek AJ and Iatridis JC. Height and torsional stiffness are most sensitive to
1041 annular injury in large animal intervertebral discs. *Spine J* (2012); 12 (5): 425-32.

1042 [62] Carragee EJ, Don AS, Hurwitz EL, Cuellar JM, Carrino JA, Herzog R. 2009
1043 ISSLS Prize Winner: Does discography cause accelerated progression of
1044 degeneration changes in the lumbar disc: a ten-year matched cohort study. *Spine*
1045 (Phila Pa 1976) (2009);34:2338-2345.

1046 [63] Koeller W, Muehlhaus S, Meier W, Hartmann F. Biomechanical properties of
1047 human intervertebral discs subjected to axial dynamic compression—influence of
1048 age and degeneration. *J Biomech* (1986);19:807-816.

1049 [64] Setton LA, Chen J. Mechanobiology of the intervertebral disc and relevance to
1050 disc degeneration. *J Bone Joint Surg Am* (2006);88 Suppl 2:52-57.

1051 [65] Koeller W, Meier W, Hartmann F. Biomechanical properties of human
1052 intervertebral discs subjected to axial dynamic compression. A comparison of lumbar
1053 and thoracic discs. *Spine* (Phila Pa 1976) (1984);9:725-733.

1054 [66] Brayda-Bruno M, Tibiletti M, Ito K, Fairbank J, Galbusera F, Zerbi A, Roberts S,
1055 Wachtel E, Merkher Y. Advances in the diagnosis of degenerated lumbar discs and
1056 their possible clinical application. *Eur Spine J* (2014);23:315-323.

1057